A pollster who does some work for biopharma companies shared an insight that seems blazingly obvious when you think about: pharmaceutical companies can’t “win” the drug pricing debate. When it comes to prices, the interests of manufacturers are, in fact, diametrically opposed to those of consumers and their agents (insurers, public and private).
You can justify pricing with arguments about the cost of research and development, you can tie a price to value,...